Overview

The intern in the Epidemiology group will serve to learn the process of drug development where Epidemiologist can add value.This will include identifying incidence and prevalence figures for both the US and ex-US markets, consulting on observational study design, and conducting systematic and targeted literature reviews. Deliverables will include formal reports on disease state epidemiology.

Learning Outcomes

1.Understand the contributions Epidemiology makes within the drug development process

2.Use real-world and clinical data to refine population size and characteristics for disease targets as clinical development progresses, in both rare disease and prevalent disease areas.

3.Support regulatory submission activities including authoring epidemiology sections of orphan or breakthrough designation applications and dossiers and helping design post-marketing commitment studies

Qualifications

*Masters degree or equivalent in Epidemiology, Outcomes Research, Biostatistics, or other related public health field.

*Must be pursuing PhD, ScD or equivalent doctorate in Epidemiology, with at least 1 year completed.

*Strong communication skills, both written and oral

*Advanced knowledge in observational research design

*Legal authorization to work in the U.S.

*At least 18 years of age prior to scheduled start date

About Us

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2022, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2023 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.

Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Alnylam is an E-Verify employer.